Core Viewpoint - Corcept Therapeutics (CORT) has seen an 11.8% increase in share price over the past four weeks, closing at $47.27, with analysts suggesting a potential upside of 43% based on a mean price target of $67.60 [1] Price Targets and Analyst Consensus - The average price target for CORT ranges from a low of $45 to a high of $78, with a standard deviation of $13.32, indicating variability in analyst estimates [1] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [4] Earnings Estimates and Market Sentiment - Analysts have shown growing optimism regarding CORT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 1.3% increase in the Zacks Consensus Estimate for the current year [5] - CORT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential upside [5] Limitations of Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][4] - Empirical research indicates that price targets set by analysts rarely reflect actual stock price movements, suggesting that investors should approach these targets with skepticism [3][4]

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting that while price momentum can be profitable, ensuring its longevity is crucial for success [1][2]. Group 1: Stock Performance - Corcept Therapeutics (CORT) has shown a solid price increase of 37.1% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 11.8% in the last four weeks, suggesting that the upward trend is still intact [5]. - CORT is currently trading at 98.4% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - CORT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of this ranking system [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks with sufficient fundamental strength to maintain their upward momentum [3]. - In addition to CORT, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [8].

Our initiation report " "Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth" on September 15, 2024 became so long we had to save some content for this new report which focuses on the important near term news flow for Brown University Ab.ScB Civil Engineering/Urban Studies, Stanford University MBA, Morgan Guaranty Trust, Fiduciary Trust International ,Tanaka Capital Mgmt., Author "Digital Deflation" McGraw-Hill 2004. Appeared on CNBC and Bloomberg TV 40+ times. Manages the TANAKA Growth Fu ...

Corcept Therapeutics' (CORT) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. The successful development and commercialization of its pipeline candidates will be an added boost to the company. Let's dig deeper. Reasons to Invest in CORT Stock Good Rank and Rising Estimates: Cor ...

Shares of Corcept Therapeutics (CORT) have gained 31.1% over the past four weeks to close the last trading session at $46.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $65.40 indicates a potential upside of 41.3%. The average comprises five short-term price targets ranging from a low of $45 to a high of $78, with a standard deviation of $12.46. While the lowest estimate in ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Our ...

Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it "is impressive and difficult to ignore." Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who ca ...

Corcept Therapeutics (CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks. The company's sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing's syndrome is expected to be filed in ...

Shares of Corcept Therapeutics Incorporated (CORT) have gained 46.2% in the past six months against the industry's decline of 2%. The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. Factors Driving CORT Stock in the Given Time Frame Corcept has made steady progress ...

Investors might want to bet on Corcept Therapeutics (CORT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. S ...